MedPath

Effect of alogliptin , a DPP-4 inhibitor, on markers of lipid metabolism in type 2 diabetic patients

Phase 4
Conditions
type 2 diabetic patients
Registration Number
JPRN-UMIN000011470
Lead Sponsor
ara Hospital Kinki University Faculty of Medicine
Brief Summary

The presentation at the 55th Japan Diabetes Society Annual Scientific Meeting

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

patients receiving insulin therapy; severe liver or renal dysfunction; patients with hypersensitivity to alogliptin; patients that had their hypoglycemic agents changed within three months; pregnant women or breast-feeding mothers; and excessive alcohol drinkers.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath